Literature DB >> 30811596

Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone.

M Zakariyyah Aumeeruddy1, M Fawzi Mahomoodally1.   

Abstract

Despite the significant advances in screening methods for early diagnosis, breast cancer remains a global threat and continues to be the leading cancer diagnosed in women, requiring effective therapy. Currently, combination therapy has become the hallmark of breast cancer treatment due to the high incidence of tumor recurrence and disease progression after monotherapeutic treatments, including surgery, radiotherapy, endocrine therapy, and chemotherapy. Over the past decades, there has been considerable interest in studying the anticancer effect of bioactive phytochemicals from medicinal plants combined with these conventional therapies. The rationale for this type of therapy is to use combinations of drugs that work by different mechanisms, thereby decreasing the likelihood that cancer cells will develop resistance, and also reduce the therapeutic dose and toxicity of single treatments. Three agents have received great attention with regard to their anticancer properties: 1) piperine, a dietary phytochemical isolated from black pepper (Piper nigrum L.) and long pepper (Piper longum L.); 2) sulforaphane, an isothiocyanate mainly derived from cruciferous vegetables; and 3) thymoquinone, the active compound from black seed (Nigella sativa L.). This review focused on the combined effect of these 3 compounds on conventional cancer therapy with the objective of observing enhanced efficacy compared with single treatments. This review also highlights the importance of the nanoformulation of such bioactive phytochemicals that could enhance their bioavailability by providing an efficient targeted delivery system with a reduced systemic dose while resulting in a more efficient dosing at the target site.
© 2019 American Cancer Society.

Entities:  

Keywords:  breast cancer; combination therapy; phytochemicals; piperine; sulforaphane; thymoquinone

Mesh:

Substances:

Year:  2019        PMID: 30811596     DOI: 10.1002/cncr.32022

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  Formulation, Cellular Uptake and Cytotoxicity of Thymoquinone-Loaded PLGA Nanoparticles in Malignant Melanoma Cancer Cells.

Authors:  Wisam Nabeel Ibrahim; Luqman Muizzuddin Bin Mohd Rosli; Abd Almonem Doolaanea
Journal:  Int J Nanomedicine       Date:  2020-10-20

2.  Effect of Combining 0.01% Atropine with Soft Multifocal Contact Lenses on Myopia Progression in Children.

Authors:  Jenny Huang Jones; Donald O Mutti; Lisa A Jones-Jordan; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2022-02-25       Impact factor: 2.106

3.  miR-519 regulates the proliferation of breast cancer cells via targeting human antigen R.

Authors:  Lili Ren; Yong Li; Qun Zhao; Liqiao Fan; Bibo Tan; Aimin Zang; Hua Yang
Journal:  Oncol Lett       Date:  2019-12-20       Impact factor: 2.967

4.  Circulating amino acids and amino acid-related metabolites and risk of breast cancer among predominantly premenopausal women.

Authors:  Oana A Zeleznik; Raji Balasubramanian; Yibai Zhao; Lisa Frueh; Sarah Jeanfavre; Julian Avila-Pacheco; Clary B Clish; Shelley S Tworoger; A Heather Eliassen
Journal:  NPJ Breast Cancer       Date:  2021-05-18

5.  Antioxidant and Anticancer Activities of Heart Components Extracted from Iraqi Phoneix Dactylifera Chick.

Authors:  Mustafa F Hameed; Ihsan A Mkashaf; Ali A A Al-Shawi; Kawkab A Hussein
Journal:  Asian Pac J Cancer Prev       Date:  2021-11-01

Review 6.  Bioactive Compounds: Multi-Targeting Silver Bullets for Preventing and Treating Breast Cancer.

Authors:  Nethaji Muniraj; Sumit Siddharth; Dipali Sharma
Journal:  Cancers (Basel)       Date:  2019-10-15       Impact factor: 6.639

7.  Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.

Authors:  Saira Justin; Jochen Rutz; Sebastian Maxeiner; Felix K-H Chun; Eva Juengel; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

Review 8.  Brassicaceae-Derived Anticancer Agents: Towards a Green Approach to Beat Cancer.

Authors:  Luigi Mandrich; Emilia Caputo
Journal:  Nutrients       Date:  2020-03-24       Impact factor: 5.717

9.  Anti-Cancer Effect of Cordycepin on FGF9-Induced Testicular Tumorigenesis.

Authors:  Ming-Min Chang; Siou-Ying Hong; Shang-Hsun Yang; Chia-Ching Wu; Chia-Yih Wang; Bu-Miin Huang
Journal:  Int J Mol Sci       Date:  2020-11-06       Impact factor: 5.923

10.  Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights.

Authors:  Mohammed Moustapha Anwar; Manal Shalaby; Amira M Embaby; Hesham Saeed; Mona M Agwa; Ahmed Hussein
Journal:  Sci Rep       Date:  2020-09-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.